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Various Forms of Chemically Induced Liver
Injury and Their Detection by Diagnostic
Procedures*'
by H. J. Zimmermant
A large number of chemical agents, administered for therapeutic or diagnostic purposes, can
produce various types of hepatic injury by several mechanisms. Some agents are intrinsically
hepatotoxic, and others produce hepatic injury only in the rare, uniquely susceptible individual.
Idiosyncrasy of the host is the mechanism for most types of drug-induced hepatic injury. It may
reflect allergy to the drug or a metabolic aberation of the host permitting the accumulation of
hepatotoxic metabolites. The syndromes of hepatic disease produced by drugs have been clas-
sified as hepatocellular, hepatocanalicular, mixed and canalicular. Measurement ofserum enzyme
activities has provided a powerful tool for studies ofhepatotoxicity. Their measurement requires
awareness of relative specificty, knowledge of the mechanisms involved, and knowledge of the
relationship between known hepatotoxic states andelevated enzyme activities.
Drug-induced liver disease accounts for only a
small proportion (less than 5%) of instances of
jaundice in general hospitals (1,2). As a cause of
severe, acute, hepatic disease with hepatic
failure, however, adverse reactions to thera-
peutic agents (for example, halothane or
isoniazid) figure more prominently. Hepatic
necrosis induced by drugs accounts for 25 to 30%
of instances of fulminant hepatic failure (3).
Hepatic damage caused by therapeutic agents is
best reviewed in the context of the general
aspects of hepatotoxicity (4). These include the
character of the injury and the presumed mech-
anisms and circumstances of exposure to the
respective agent.
* Portions of this text were previously published in the
Israel Journal of Medical Sciences [10:386, 328 (1974)]. These
are reproduced with permission of the Israel Journal of
Medical Sciences.
t Veterans Administration Hospital, Washington, D.C.
TypesofDrug-Induced
Hepatic Disease
Chemical agents can produce several types of
hepatic injury (Table 1). The injury may be
cytotoxic, that is, characterized by necrosis or
degeneration of the hepatic parenchyma, or
cholestatic, that is, manifested by arrested bile
flow and jaundice, but relatively little paren-
chymal injury. Some drugs characteristically
produce injury that includes elements of both
types and is referred to as mixed. The cytotoxic
form includes necrosis (zonal, diffuse, and mas-
sive), steatosis, or combinations of necrosis and
steatosis. Cholestatic injury may be bland, that
is, manifested only by bile stasis, without signifi-
cant inflammatory changes in the liver, as in that
produced by the C-17 alkylated anabolic or con-
traceptive steroids; or it may be accompanied by
impressive portal area aggregates of inflamma-
tory cells, as in the cholestatic injury induced by
erythromycin estolate or chlorpromazine.
The correlation between the morphological
June 1976 3type of hepatic injury and the clinical and
biochemical abnormalities is quite consistent.
Hepatic necrosis induced by drugs leads to a syn-
drome which resembles that of viral hepatitis
with markedly elevated transaminase valves and
relatively slight elevations of the alkaline
phosphatase levels. Most important is the tenden-
cy for this syndrome to present itself as massive
hepatic necrosis and liver failure.
The hepatic steatosis produced by tetracycline
resembles the histological picture the fatty liver
of pregnancy and leads to similar biochemical
features and clinical manifestations. Jaundice is
usually modest and the transaminase values are
only moderately elevated, but the syndrome of
hepatic failure with a fatal outcome can develop.
Cholestatic injury resembles extrahepatic ob-
structive jaundice in its manifestation. The clin-
ical picture is dominated by jaundice and itching.
the biochemical parameters include modest
transaminase elevations and alkaline phos-
phatase activities that resemble those of obstruc-
tive jaundice. This is the picture in the chole-
static jaundice associated with portal inflamma-
tion (hepatocanalicular jaundice). (4). Alkaline
phosphatase activities are more modestly ele-
vated in the bland cholestasis induced by C-17
alkylated steroids (canalicular jaundice) (4).
Some drugs produce a mixed pattern of hepatic
injury that includes both cytotoxic and chole-
static features. Hepatocanalicular jaundice with
prominent parenchymal injury accompanying the
predominantly cholestatic picture has been
characterized as mixed-hepatocanalicular jaun-
dice. Hepatocellular injury in which a predom-
inantly cytotoxic form of damage is accompanied
by very high alkaline phosphatase values has
been designated mixed-hepatocellular jaundice
(4).
Precise description of the phenomenology of
the forms of drug-induced injury may have sev-
eral advantages. The type of injury has a clear
bearing on the prognosis. The more prominent
the hepatocellular injury, the more grave the syn-
drome, with hepatic failure and a fatal outcome
possible (4). The more cholestatic the injury and
the less prominent the parenchymal damage, the
better the immediate prognosis. The mortality
rate in hepatocellular jaundice ranges from 10 to
50%, while in drug-induced cholestaticjaundice it
is less than 1%. Furthermore, the type of injury
is related tothetherapeutic category ofdrug. For
example, the antidepressants tend to produce
hepatocellular injury, the anticonvulsants lead to
mixed-hepatocellular injury, the tranquilizers, to
hepatocanalicular or mixed-hepatocanalicular in-
jury and the anabolic and contraceptive steroids
produce the canalicular type ofinjury (5).
Chronic hepatic disease can also result from
drug-induced injury. Acute hepatocellular injury
induced by cinchophen, iproniazid and repeated
exposure to halothane has been reported to lead
to cirrhosis of the macronodular type (5). Pro-
longed administration of methotrexate appears
to lead, in some patients, to cirrhosis of the
macro or micronodular type (6). In some patients,
the hepatic injury induced by oxyphenisatin
shows features of chronic active hepatitis, in-
cluding cirrhosis (7). Cholestatic injury induced
by chlorpromazine, organic arsenicals, tolbuta-
mide, methyltestosterone and contraceptive
steroids has led to instances of a cirrhosis re-
sembling the "primary biliary" type (5). The
Budd-Chiari syndrome, with congestive cirrhosis,
can result from thrombotic occlusion of the he-
patic veins induced by contraceptive steroids or
by the venoocclusive disease and centrolobular
hepatic sclerosis secondary to urethane poisoning
(5).
Mechanisms of Injury
The chemical agents that produce hepatic
damage fall into two broad categories: those that
have the intrinsic property of injuring the liver
(intrinsic or predictable hepatotoxins) and those
that damage the liver of uniquely susceptible
hosts (idiosyncracy-dependent or unpredictable
toxins) (Table 2). The first group is recognizable
by the high incidence of toxicity in exposed in-
dividuals, dependence on dose and reproducibili-
ty of the injury in a variety of species. Agents
which produce hepatic injury in a small propor-
tion of exposed individuals, whose toxicity is not
dose-dependent and which do not produce hepatic
damage in experimental animals, are recognized
to depend on host idiosyncrasy rather than on the
intrinsictoxicity ofthe agent (4,5,8,9).
Intrinsic hepatotoxins appear to include at
least two subcategories, direct and indirect
(Table 2). Direct hepatotoxins are protoplasmic
poisons capable of injuring many tissues, par-
ticularly the liver. The prototype, carbon tetra-
chloride (CCI.) disrupts all elements of the
hepatocyte including the endoplasmic reticulum,
mitochondria, lysosomes, and plasma membranes
and, indeed, leads to almost immediate, destruc-
tive intracellular chaos. The membrane injury ap-
pears to result from peroxidative damage of the
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I
rzlipid components, wrought mainly by a metabo-
lite ofthe CC14.
Indirect hepatotoxins are antimetabolites or
related compounds, which produce hepatic injury
by the diversion or competitive inhibition of
essential metabolites or by other forms of in-
terference with specific metabolic or secretory
processes of the hepatocyte. Indirect hepatotox-
ins cripple the hepatocyte selectively by inter-
ference with a specific pathway, while direct tox-
ins appear to produce generalized, indiscriminate
intrahepatocyte damage. Indirect hepatotoxins
can be cytotoxic, producing steatosis or necrosis,
or cholestatic producingjaundice (4,5).
Hepatic injury which depends on host idiosyn-
cracy can also be divided into two types. The
liver injury produced by some drugs after a fixed
latent period (usually one to four weeks) is usual-
ly accompanied by systemic (fever, rash, eosino-
philia) and histological (tissue eosinophilia or
granulomas) features which suggest hypersensi-
tivity to the drug as the cause. Often, the cir-
cumstances under which the injury occurs, and
the response to a challenge dose, confirm drug
allergy in these instances, and the inference is
drawn that the drug or a metabolite has acted as
a hapten (4,5,8,9).
The liver damage induced by other drugs, how-
ever, also in uniquely susceptible individuals,
after a widely variable latent period and unac-
companied by ancillary features suggestive of
hypersensitivity, may be deduced to be the result
of some other mechanism, perhaps a metabolic
aberration of the idiosyncratic patient, permit-
ting the accumulation of hepatotoxic metabolites
(4,5).
Knowledge of presumed mechanism and type
of hepatic injury permits the classification of
hepatotoxic agents shown in Table 2. While this
classification may be subject to change as knowl-
edge of mechanisms of injury increases, it has
proved useful.
Hepatic InjuryDueto IntnnsicToxicityofDrugs
Direct Hepatotoxins
There are no known direct hepatotoxins that
are used as therapeutic or diagnostic agents.
CC14, formerly used as a vermifuge, has been
largely abandoned, and tannic acid, which was at
one time employed to treat burns and more re-
cently in barium sulfate preparations to improve
the quality of colonic radiographic studies, has
been dropped from clinical use or employed in
subtoxic concentrations for x-ray studies.
Indirect Hepatotoxins
Indirect hepatotoxins include a number of
therapeutic agents (Table 2). Among the cytotox-
ic, indirect toxins are some antibiotics (e.g.,
tetracycline) and a large number of agents em-
ployed in the chemotherapy of neoplastic disease.
Many of these agents produce hepatic steatosis
by interfering with synthesis of appropriate apo-
protein or with assembly of the lipoprotein com-
plex required for the transport of lipid from the
liver (5). Some drugs (e.g., urethane) that are
categorized as cytotoxic indirect hepatotoxins
produce necrosis by a mechanism that remains to
be understood. Perhaps it is analogous to the
necrogenic effect of bromobenzene which may be
related to covalent binding to cytoplasmic pro-
teins (10), although the means by which this leads
to necrosis is obscure.
Tetracycline (and its congeners) is an antibiotic
in clinical use which is illustrative of the indirect,
cytotoxic hepatotoxins. High doses lead, in pa-
tients and experimental animals, to a diffuse
vacuolization of hepatocytes that consists of tiny
droplets of lipid and nonlipid material. It appears
as a clinically important lesion only when high
blood levels of tetracycline are produced by IV
doses in excess of 1.5 g/day. The lesion seems
particularly prone to occur if the recipient is in
the last trimester of pregnancy or has renal
disease. Smaller IV doses or oral administration
usually produce no clinical evidence of hepatic
disease, although minor degrees of steatosis can
be observed in biopsy sections of the liver even
after oral doses (5).
The mechanism for the steatosis has been dem-
onstrated to be rapid inhibition by tetracycline of
movement of lipid from the liver (5,11). Whether
this is related to the known ability of these an-
tibiotics to interfere with protein synthesis,
perhaps by binding of tRNA or by interference
with some other element of the complex system
of synthesis or assembly of the lipoprotein nec-
essary to transport the lipid from the liver, is
unknown (5,11).
Ethanol also warrants classification as a drug
which is an indirect hepatotoxin. It leads to fatty
metamorphosis by a number ofadverse effects on
hepatocyte metabolism (12), but this is not within
the scope ofthis paper.
Cholestatic Indirect Hepatotoxins
These toxins produce jaundice or impaired
liver function by selective interference with
hepatic mechanisms for excretion of substances
Environmental Health Perspectives 6into a canaliculus or uptake from the blood (5).A
number of C-17 alkylated anabolic steroids are in
this category. The effect of these agents is dose-
related, but modified by the individual suscepti-
bility ofthe recipient. Hepatic dysfunction is pro-
duced in most individuals, but jaundice in only a
few. Impairment of bromosulfhalein excretion oc-
curs within a few days. Continued administration
of the agent usually leads to a plateau or even to
some decrease in the degree of abnormality of
hepatic function. This would suggest that adjust-
ment to and compensations for the adverse ef-
fects of the drug occur in most individuals, and
that patients who develop jaundice after pro-
longed administration ofone ofthese steroids are
unable to make this adjustment, perhaps on a
genetic basis (4).
Similar to this phenomenon is the high inci-
dence of a relatively slight degree of hepatic
dysfunction in women who take oral contracep-
tive steroids, which consist of C-17 alkylated
estrogen and progesterone derivatives. Curious-
ly, the oral contraceptive agents are particularly
likely to produce jaundice in women who have
had the benign, cholestatic jaundice of pregnan-
cy, a syndrome with a probable genetic basis (5).
Also probably related to this phenomenon is the
impairment of liver function produced by estradi-
ol and a number ofother estrogenic agents (13).
The mechanism for the impaired function in-
duced by these anabolic, progestational and
estrogenic steroids is unknown. The available
evidence suggests precise structural require-
ments, namely, an alkyl group at C-17. Testos-
terone, which lacks this type of substituent, does
not lead to impaired function, while methyltes-
tosterone, identical in structure except for the C-
17 methyl substituent, does. A number of other
agents with C-17 alkyl substituents also produce
jaundice. This suggests the still unconfirmed
hypothesis that these steroids might lead to im-
paired excretion of bile and its constituents by
competitive interference with the trans-
canalicular transport (4) or excretory (14) role of
a bile acid or other metabolite.
A variant of the cholestatic type of indirect
hepatotoxicity includes that caused by agents
that produce unconjugated hyperbilirubinemia
and interfere with the uptake of foreign dyes
from sinusoidal blood. In this category are
flavaspidic acid, gallbladder dyes, and rifampicin
(5,9). Rifampicin also appears to interfere with
clearance of bilirubin and foreign dyes by com-
petitive inhibition of their biliary excretion (15).
Novobiocin can also lead to unconjugated hyper-
bilirubinemia, especially in neonates, apparently
by interfering with bilirubin conjugation (9).
Hepatic Injury DueTo Host Idiosyncrasy
Many drugs produce hepatic injury, unpredic-
tably, in a small proportion of recipients. The he-
patic injury appears to be an expression of
unique, individual susceptibility rather than ofin-
trinsic toxicity of the offending agent (4,5,8,9).
Some analyses have referred to these as hyper-
sensitivity reactions, a designation that tacitly
assumes or explicitly regards the mechanism to
be that of drug allergy, and the two terms have
been employed interchangeably in this context.
Indeed some instances, described below, of drug
induced injury probably are a manifestation of
allergy. Others appear to represent a different
mechanism, presumably an aberrant metabolic
pathway for the drug in the susceptible patient.
Accordingly, to avoid confusion, hepaticinjury in-
duced by a drug sporadically, unpredictably and
in low incidence should be designated as an idio-
syncratic response to the drug. The term hyper-
sensitivity should be reserved for hepatic injury
which appears to result from allergy to the drug
(5).
Hypersensitivity
Allergy is presumed to be the mechanism when
the hepatic injury is characterized by (a) a rela-
tively fixed "sensitization" period of one to four
weeks; (b) prompt recurrence of hepatic dysfunc-
tion or jaundice on readministration of small
doses of the agent; (c) a high incidence of fever,
rash and eosinophilia; (d) eosinophil-rich inflam-
matory infltration, or granulomas in the liver;
and (e) the coincidence of blood dyscrasia that
also appears to depend on hypersensitivity for its
pathogenesis (8). These features, however, pro-
vide only circumstantial evidence for drug
hypersensitivity as the cause of hepatic disease
(5). Efforts to demonstrate a role for humoral or
cell-mediated immunity by the study of clinical
cases have yielded variable results, and there are
noexperimental counterparts.
Indeed, no firm evidence for the role of hyper-
sensitivity in drug induced hepatic injury has
been available. The significance of the demon-
stration of antiliver antibodies in apparently
drug-induced hepatic disease and of antimito-
June 1976 7chondrial antibodies in the serum ofpatients with
several forms of apparently drug-induced injury,
is uncertain (5). The studies of Paronetto and
Popper (16) and those of Opolon et al. (17), sug-
gest that in vitro tansormation of lymphocytes
can be employed to demonstrate a relationship
between an administered drug and hepatic injury
in the recipient. While this technique has been
useful for the study ofgeneralized hypersensitivi-
ty reactions to drugs (17), a firm relationship to
hepatic injury has not yet been shown.
The search for evidence of drug allergy as the
cause of hepatic injury is hampered by the re-
alization that the anitgen responsible for the
presumed allergic state might be an unknown
metabolite of the drug rather than the adminis-
tered molicule (18). Despite the lack of concrete
evidence, drugallergy is probably responsible for
many instances of hepatic disease. For example,
sulfonamides, p-aminosalicylic acid, chlorpro-
mazine, organic arsenicals, oxyphenisatin, meth-
yldopa and halothane produce hepatic injury
under circumstances which suggest that drug
allergy plays an important role (5). Other drugs,
however, produce hepatic injury in an equally
small proportion ofexposed individuals, but unac-
companied by clinical features that suggest drug
allergy (4,5).
Even agents which appear to satisfy the cri-
teria for hypersensitivity warrant closer scru-
tiny. While chlorpromazine, erythromycin esto-
late and triacetyloleandomycin produce clinically
apparent hepatic injury in approximately 1% of
recipients, the incidunce of hepatic dysfunction
has been observed to be much higher (40-50%)
(4,5). These figures are too high to permit the
assumption of hypersensitivity alone as the
mechanism for the hepatic abnormality. Further-
more, some agents (e.g., penicillin) which pro-
duce overt generalized hypersensitivity, rarely
produce hepatic injury (5). These observations
have led to the hypothesis that some agents have
a mildly adverse effect on the liver, which, when
accompanied by hypersensitivity, may be ex-
pressed a overt liver disease (5,19). Support for
this hypothesis has derived from studies utilizing
suspensions of Chang liver cells maintained in
tissue culture, suspensions ofrat hepatocytes and
the perfused rat liver (20-24). These studies have
demonstrated a correlation between the adverse
effects on these in vitro models of several
phenothiazines (20-22) and several erythromycin
derivatives (23,24), and the potential of these
agents to cause hepatic injury in patients.
Metabolic Abnormality
A number of drugs produce hepatic injury in a
small proportion of exposed individuals, under
conditions that do not conform to the criteria for
hypersensitivity as the mechanism (4,5,19).
These reactions are characterized by a variable
latent period rather than a fixed period of sen-
sitization, no accompying rash, fever, or eosino-
philia, no eosinophilic or granulomatous inflam-
matory response in the liver, and failure to re-
produce the hepatic injury with a single chal-
lenge dose ofthe drug. To produce the hepatic in-
jury caused by these agents seems to require re-
administration ofthe drug for a period of days or
weeks. The possibility has alreadybeen cited that
this form of hepatic injury results from a meta-
bolic abnormality that permits very high levels of
the drug or the accumulation of hepatotoxic
metabolites. Evidence to support this view, how-
ever, remainstobe developed.
The hepatic injury that results from host idio-
syncrasy to drugs may be cytotoxic, cholestatic
or mixed (4,5). The mechanism by which host
idiosyncrasy induces cytotoxic or cholestatic
jaundice is unknown. A look at the phenomenon
ofthe curious form ofhepaticinjury that has been
observed after halothane anesthesia (25), pro-
vides a basis for fruitful speculation (19). The in-
cidence of halothane-induced jaundice is very
low. Most observers consider it to be the result of
allergy to the agent. This view is supported by
the occurrence of fever and eosinophilia in more
that 50% of patients with apparent halothane-
induced jaundice, and by the observation that
previous exposure to halothane appears to pre-
dispose to hepaticinjury form the anesthetic (19).
Not all patients with jaundice, however, have col-
lateral evidence of allergy after halothane ex-
posure. Furthermore, the nature of the hepatic
lesion observed in many fatal cases, centrizonal
necrosis (26), is much like that produced by CC14
(19). The lesion produced by CC04 appears to be
caused mainly by a metabolite (the free radical,
CC13) (27). The centrizonal localization of CC04
necrosis has been attributed to the relative con-
centration in the centrizonal area of drug-
metabolizing enzyme systems (28). Accordingly,
the centrilobular necrosis observed in fatal cases
of halothane- and methoxyfluorane-induced jaun-
dice, suggests that individuals whose metabolic
aberration permits production or accumulation of
hepatotoxic metabolites may develop, by a simi-
lar mechanism, thelesion which resembles that of
CC14 (19). The metabolic aberration responsible
Environmental Health Perspectives 8for the enhanced susceptibility might be genetic
or acquired as the result of prior exposure to the
agent or to other drugs and chemicals (19). Com-
bined effects of generalized hypersensitivity and
mild toxicity due to hepatotoxic metabolites
might, in a manner similar to that proposed for
other drugs, also be responsible for the hepatic
injury ofhalothane (19).
This inference would suggest the hypothesis
that the type of hepatic injury resulting from
idiosyncratic metabolism of a drug depends on
the nature ofthe hepatotoxic metabolite (19). Ifit
injured, in a manner analogous tothat ofCC14, the
membranes of intracytoplasmic organelles, it
would produce lesions like those of the direct
hepatotoxins. If the metabolite resembled the
mediators of cytotoxic or cholestatic indirect
hepatotoxins, the respective lesions might be ex-
pected. It may also be speculated that the form of
hepatic injury produced as a manifestation of
drug allergy might depend on tissue antibodies in
the respectively injured cell type, or on localiza-
tion to the respective cell type of tissue-
damaging antigen antibody complexes or cyto-
lytic factors from stimulated lymphocytes. Evi-
dence forthese speculations remains wanting.
Analysis of Hepatotoxic Reactions Induced by
Drugs According to Clinical Circumstances of
Exposure
Some of the many drugs which can produce
hepatic injury are listed in Table 3, according to
category ofclinical use. Table 3indicates the type
of injury produced and the apparent mechanism
oftoxicity. For some drugs,_there is sufficient in-
formation to describe the type of hepatic injury
with some confidence. For the drugs designated
as indirect toxins, there is reasonable experimen-
tal basis to support this mechanism ofinjury. For
most drugs, the mechanism remains largely spec-
ulative and no distinction has been made in the
Table between apparent hypersensitivity or met-
abolic abnormality asthebasis for idiosyncrasy.
Despite the difficulties in assembling reliable
data on drug-induced hepatic injury, a number
of general relationships between the category of
pharmacological effect and the apparent mech-
anism and form of hepatic injury can be derived.
As mentioned earlier, the hepatic injury owing to
all the tranquilizing drugs is usually hepato-
canalicular, and it appears, at least in part, to be
induced by hypersensitivity, while almost all the
antidepressants produce hepatocellular injury as
a result of host idiosyncrasy, not necessarily of
the drug allergy type. The hydrazine derivatives
used in the treatment of tuberculosis produce
hepatic injury, similar to that of the chemically
related antidepressants (5). Diphenylhydantoin
and other anticonvulsant drugs generally pro-
duce hepatocellular or mixed-hepatocellular in-
jury apparently induced by hypersensitivity. The
C-17 alkylated steroids usually produce canalic-
ular jaundice ("bland cholestasis") as indirect
hepatotoxicity. The patterns of injury are less
consistent for the oral antidiabetic drugs, the an-
tithyroid drugs and sulfonamide derivatives.
These observations of the similarity of the
hepatic injury produced by different members of
a class of therapeutic agents pose an intriguing
question. Is the mechanism for, and type of toxic
effect on the liver related to the mechanism for
the intended therapeutic effect on other organs?
Serum Enzyme Measurement in Expermental
Hepatotoxicity
Serum enzymology and experimental hep-
atotoxicity have had an intimate relationship.
Development of clinically or experimentally use-
ful enzyme tests for the recognition of hepatic
disease [e.g., glutamate-oxaloacetate trans-
aminase (aspartate aminotransferase; GOT), or-
nithine carbamyl transferase (OCT), sorbitol
dehydrogenase (SDH), arginase, guanase, isoci-
trate dehydrogenase (ICDH)]has depended on
the study of the effects of experimental hepato-
toxic states on serum levels of the enzyme. For
this, known hepatotoxins, e.g. carbon tetrachlo-
ride, employed under standardized conditions,
have been used.
Measurement of serum enzyme activities has
provided a powerful tool for studies of hepatotox-
icity. It has been employed in testing for toxicity
of agents whose effects are unknown and in stud-
ying the circumstances and factors which influ-
ence the effects of known hepatotoxins. Study of
factors that enhance -(e.g., phenobarbital pre-
treatment) or depress (e.g., inhibition of me-
tabolism) CC14 toxicity has been critically aided
by monitoring the extent ofinjury with serum en-
zyme assay. Moreover, demonstration of the
promptness of injury is facilitated by serum en-
zyme measurement [GOT, glutamate pyruvate
transaminase (alanine aminotransferase, GPT),
ICD, OCT, SDH], as is identification of organelle
injury, by measuring serum levels of enzymes
June 1976 9Table 3. Mechanism oftypes ofhepatic injuryproduced by drugs in various therapeutic categories.
Pattern ofinjury
Hepatocellular or Hepatocanalicular or
Type ofagent mixed hepatocellular mixed hepatocanalicular Canalicular
General anesthetics Chloroforma
Trichlorethylenea
Halothane
Methoxyfluorane
Fluoroxene
Neuro-and psychotropic
agents
Tranquilizers
Antidepressants
Anticonvulsants
Drugs employed in
rheumatic and
musculoskeletal disease
and as analgesics
Iproniazid and congeners
Amytriptylene
Diphenylhydantoin
Phenylacetylurea and
congeners
Cinchophen
Zoxazolamine
Ibufenac
Indomethacin
Phenylbutazone
Salicylatesb
Acetaminophenc
Probenecid
Chlorpromazine and related
phenothiazines
Ectylurea
Chloridiazepoxide
Diazepam
Imipramine
Propoxyphene
Drugs used in endocrine
disease or as hormonal
substitutes
Propylthiouracil
Carbutamide
Metahexamide
Acetohexamide
Methimazole
Thiouracil
Chlorpropamide
Tolbutamide
C-17 alkylated anabolic
steroidsc
Contraceptive steroidsc
Estradiolc
Antimicrobial agent
Agents used in cardio-
vascular disease
Antineoplastic chemo-
therapeutic agents
Tetracycline and congenersc
Chloramphenicol
Triacetyloleandomycinb
Penicillin
Griseofulvin
Paraminosalicylic acid
Isoniazid
Ethionamide
Pyrazinamide
Rifampicin
Sulfonamides
Sulfones
Phenindione
Procainamide
Quinidine
a-Methyldopa
Nicotinic acid
Papaverine
Cause steatosisc
Actinomycin D
4-Aminopyrazolo
pyrimidine
L-Asparaginase
Azacytidine
Azauridine
Bleomycin
Cycloheximide
Erythromycin estolate
Novobiocinc
Rifampicinc
Organic arsenicals
Nitrofurantoin
Idoxuridine
Xenylamine
Ajmaline
(?)p-Aminobenzylcaffeine
hydrochloride
4,4'-Diaminodiphenylamine
Busulfan
Azathioprine
Environmental Health Perspectives 10TableS. Mechanism oftypes ofhepatic injury produced by drugs in various therapeutic categories 4Cont'd.).
Pattern ofinjury
Hlepatocellular or Hepatocanalicular or
Type of agent mixed hepatocellular mixed hepatocanalicular Canalicular
Antineoplastic Cause steatosis
chemotheropeutic Chromomycin
agents (Cont'd.) Mitomycin
N-Diazoacetylglycine
hydrazide
Puromycin
Methotrexate
(also causes cirrhosis)
Cause necrosis
Calvacinc
Mithramycin'
Urethanec
Cyclophosphamide
Chlorambucil
6-Mercaptopurinec
Miscellaneous agents Tannic acidc Carbamazepine
Trimethobenzamide
Tripelennamine
Oxyphenisatin
Phenazopyridine
a Direct hepatotoxin.
I Possibly indirect hepatotoxin.
c Indirect hepatotoxin.
All otheragentsapparentlydepend on hostidiosyncrasy, eitherhypersensitivity or metabolicabnormality.
that arise in mitochondria [e.g. glutamate specificity of an enzyme test as a reflection of
dehydrogenase(GDH), mitochondrial isoenzymes hepatic disease (Table 4) and knowledge of the
(GOT-II, MDH(M)], endoplasmic reticulum [e.g., mechanisms that can lead to altered enzyme lev-
liver monoesterase (LME), glucose-6-phospha- els in the serum (Table 5) and of the relationship
tase (G-6-Pase)] and, conceivably, lysosomes. between known hepatotoxic states and elevated
Employment of serum enzymes as markers of enzyme levels.
hepatic injury requires awareness of the relative
Table 4. Groups ofserum enzymes according to theirlevels in experimental or clinicalhepatic disease.
Obstructive jaundice
andintrahepatic Chronic Diseases of
Group Enzymes" cholestasis Acute necrosis diseases other organsb
I AL PH, 5'N, LAP,GTP Markedly increased Increased Increased +
II A GOT, MDH, LDH, ALD Increased Markedly increased Increased Increased
II B GPT, ICDH, GDH Increased Markedly increased Increased Increased
IIC OCT, SDH, LDHs, guanase,
F-P-ALD, arginase Increased Markedly increased Increased +
III CPK Normal Normal Normal Increased
IV CHE Normal Decreased Decreased +
aAL PH = alkaline phosphatase; 5'N = 5' nucleotidase; LAP = leucine aminopeptidase; GTP = glutamyl transpeptidase;
LDH, = isoenzyme of lactate dehydrogenase; CPK = creatnine phosphokinase; CHE = cholinesterase; MDK = maleate
dehydrogenase; ALD = fructose diphosphate aldolase; GPT = glutamate pyruyate transaminase; ICPH = isocitrate transferase;
SDH = sorbitol dehydrogenase; F-P-ALD = fructose monophosphate aldolase.
b I = insignificant or minimal change.
11 June 1976Table 5. Mechanisms forabnormal serum enzyme levels.
Increased levels
Increased release due to
Necrosis
Increased permeability without necrosis
Increased production and release
Decreased disposition
Decreased levels
Decreased production
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